BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Horner SM, Gale M. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J Interferon Cytokine Res. 2009;29:489-498. [PMID: 19708811 DOI: 10.1089/jir.2009.0063] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev. 2011;239:99-108. [PMID: 21198667 DOI: 10.1111/j.1600-065x.2010.00977.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 75] [Article Influence: 11.2] [Reference Citation Analysis]
2 Prieto Ortíz JE, Sánchez Pardo S, Rojas Díaz EL, Huertas Pacheco SJ. Hepatitis C crónica: aspectos clínicos, serológicos y de tratamiento en dos centros de atención en Bogotá, Colombia. Rev Colomb Gastroenterol 2014;29:424-32. [DOI: 10.22516/25007440.440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Villacres MC, Kono N, Mack WJ, Nowicki MJ, Anastos K, Augenbraun M, Liu C, Landay A, Greenblatt RM, Gange SJ, Levine AM. Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infection. J Infect Dis 2012;206:780-9. [PMID: 22693231 DOI: 10.1093/infdis/jis380] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
4 Szabo G, Wands JR, Eken A, Osna NA, Weinman SA, Machida K, Joe Wang H. Alcohol and hepatitis C virus--interactions in immune dysfunctions and liver damage. Alcohol Clin Exp Res 2010;34:1675-86. [PMID: 20608905 DOI: 10.1111/j.1530-0277.2010.01255.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
5 Schoggins JW, Rice CM. Innate Immune Responses to Hepatitis C Virus. In: Bartenschlager R, editor. Hepatitis C Virus: From Molecular Virology to Antiviral Therapy. Berlin: Springer Berlin Heidelberg; 2013. pp. 219-42. [DOI: 10.1007/978-3-642-27340-7_9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 22] [Article Influence: 0.6] [Reference Citation Analysis]
6 Rosen HR. Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest. 2013;123:4121-4130. [PMID: 24084744 DOI: 10.1172/jci67714] [Cited by in Crossref: 70] [Cited by in F6Publishing: 51] [Article Influence: 8.8] [Reference Citation Analysis]
7 Schnell G, Loo YM, Marcotrigiano J, Gale M. Uridine composition of the poly-U/UC tract of HCV RNA defines non-self recognition by RIG-I. PLoS Pathog. 2012;8:e1002839. [PMID: 22912574 DOI: 10.1371/journal.ppat.1002839] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 7.9] [Reference Citation Analysis]
8 Yamauchi S, Takeuchi K, Chihara K, Honjoh C, Kato Y, Yoshiki H, Hotta H, Sada K. STAT1 is essential for the inhibition of hepatitis C virus replication by interferon-λ but not by interferon-α. Sci Rep 2016;6:38336. [PMID: 27929099 DOI: 10.1038/srep38336] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
9 Ramanan V, Trehan K, Ong ML, Luna JM, Hoffmann HH, Espiritu C, Sheahan TP, Chandrasekar H, Schwartz RE, Christine KS, Rice CM, van Oudenaarden A, Bhatia SN. Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies. Virology 2016;494:236-47. [PMID: 27128351 DOI: 10.1016/j.virol.2016.04.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
10 Sims AC, Tilton SC, Menachery VD, Gralinski LE, Schäfer A, Matzke MM, Webb-Robertson BJ, Chang J, Luna ML, Long CE. Release of severe acute respiratory syndrome coronavirus nuclear import block enhances host transcription in human lung cells. J Virol. 2013;87:3885-3902. [PMID: 23365422 DOI: 10.1128/jvi.02520-12] [Cited by in Crossref: 91] [Cited by in F6Publishing: 58] [Article Influence: 11.4] [Reference Citation Analysis]
11 Nellore A, Fishman JA. NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis. 2011;52:369-377. [PMID: 21217184 DOI: 10.1093/cid/ciq156] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
12 Ferenci P. Treatment of chronic hepatitis C—how much interferon is enough? Nat Rev Gastroenterol Hepatol 2010;7:191-3. [DOI: 10.1038/nrgastro.2010.40] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
13 Matthews SJ, Lancaster JW. Telaprevir: a hepatitis C NS3/4A protease inhibitor. Clin Ther. 2012;34:1857-1882. [PMID: 22951253 DOI: 10.1016/j.clinthera.2012.07.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
14 Kalvakolanu DV, Nallar SC, Kalakonda S. Cytokine-induced tumor suppressors: a GRIM story. Cytokine. 2010;52:128-142. [PMID: 20382543 DOI: 10.1016/j.cyto.2010.03.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
15 Negash AA, Ramos HJ, Crochet N, Lau DT, Doehle B, Papic N, Delker DA, Jo J, Bertoletti A, Hagedorn CH, Gale M Jr. IL-1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog 2013;9:e1003330. [PMID: 23633957 DOI: 10.1371/journal.ppat.1003330] [Cited by in Crossref: 266] [Cited by in F6Publishing: 252] [Article Influence: 33.3] [Reference Citation Analysis]
16 Li YP, Ramirez S, Gottwein JM, Bukh J. Non-genotype-specific role of the hepatitis C virus 5' untranslated region in virus production and in inhibition by interferon. Virology 2011;421:222-34. [PMID: 22029937 DOI: 10.1016/j.virol.2011.10.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
17 Stone AE, Mitchell A, Brownell J, Miklin DJ, Golden-Mason L, Polyak SJ, Gale MJ Jr, Rosen HR. Hepatitis C virus core protein inhibits interferon production by a human plasmacytoid dendritic cell line and dysregulates interferon regulatory factor-7 and signal transducer and activator of transcription (STAT) 1 protein expression. PLoS One 2014;9:e95627. [PMID: 24788809 DOI: 10.1371/journal.pone.0095627] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
18 Anguille S, Lion E, Willemen Y, Van Tendeloo VF, Berneman ZN, Smits EL. Interferon-α in acute myeloid leukemia: an old drug revisited. Leukemia 2011;25:739-48. [PMID: 21274002 DOI: 10.1038/leu.2010.324] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 7.3] [Reference Citation Analysis]
19 Biggins SW, Trotter J, Gralla J, Burton JR, Bambha KM, Dodge J, Brocato M, Cheng L, McQueen M, Forman L. Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol. 2013;58:969-976. [PMID: 23333445 DOI: 10.1016/j.jhep.2012.12.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
20 Neuman MG, French SW, Casey CA, Kharbanda KK, Nanau RM, Rasineni K, Mcvicker BL, Kong V, Donohue TM. Changes in the pathogenesis of alcohol-induced liver disease — Preclinical studies. Experimental and Molecular Pathology 2013;95:376-84. [DOI: 10.1016/j.yexmp.2013.10.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
21 Solodova E, Jablonska J, Weiss S, Lienenklaus S. Production of IFN-β during Listeria monocytogenes infection is restricted to monocyte/macrophage lineage. PLoS One 2011;6:e18543. [PMID: 21494554 DOI: 10.1371/journal.pone.0018543] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
22 Giugliano S, Petroff MG, Warren BD, Jasti S, Linscheid C, Ward A, Kramer A, Dobrinskikh E, Sheiko MA, Gale M Jr, Golden-Mason L, Winn VD, Rosen HR. Hepatitis C Virus Sensing by Human Trophoblasts Induces Innate Immune Responses and Recruitment of Maternal NK Cells: Potential Implications for Limiting Vertical Transmission. J Immunol 2015;195:3737-47. [PMID: 26342030 DOI: 10.4049/jimmunol.1500409] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
23 Ireton RC, Gale M Jr. RIG-I like receptors in antiviral immunity and therapeutic applications. Viruses 2011;3:906-19. [PMID: 21994761 DOI: 10.3390/v3060906] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 4.6] [Reference Citation Analysis]
24 Stone AE, Giugliano S, Schnell G, Cheng L, Leahy KF, Golden-Mason L, Gale M Jr, Rosen HR. Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog 2013;9:e1003316. [PMID: 23637605 DOI: 10.1371/journal.ppat.1003316] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
25 Thueng-in K, Thanongsaksrikul J, Jittavisutthikul S, Seesuay W, Chulanetra M, Sakolvaree Y, Srimanote P, Chaicumpa W. Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase. MAbs 2014;6:1327-39. [PMID: 25517317 DOI: 10.4161/mabs.29978] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
26 Li H, Hughes AL, Bano N, McArdle S, Livingston S, Deubner H, McMahon BJ, Townshend-Bulson L, McMahan R, Rosen HR, Gretch DR. Genetic diversity of near genome-wide hepatitis C virus sequences during chronic infection: evidence for protein structural conservation over time. PLoS One 2011;6:e19562. [PMID: 21573177 DOI: 10.1371/journal.pone.0019562] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
27 Malathi K, Saito T, Crochet N, Barton DJ, Gale M, Silverman RH. RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP. RNA. 2010;16:2108-2119. [PMID: 20833746 DOI: 10.1261/rna.2244210] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 9.3] [Reference Citation Analysis]
28 Wang T, Weinman SA. Interactions Between Hepatitis C Virus and Mitochondria: Impact on Pathogenesis and Innate Immunity. Curr Pathobiol Rep. 2013;1:179-187. [PMID: 23956955 DOI: 10.1007/s40139-013-0024-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
29 Dong C, Zafrullah M, Mixson-hayden T, Dai X, Liang J, Meng J, Kamili S. Suppression of interferon-α signaling by hepatitis E virus. Hepatology 2012;55:1324-32. [DOI: 10.1002/hep.25530] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 7.4] [Reference Citation Analysis]
30 Peterhans E, Schweizer M. BVDV: A pestivirus inducing tolerance of the innate immune response. Biologicals 2013;41:39-51. [DOI: 10.1016/j.biologicals.2012.07.006] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
31 Horner SM. Activation and Evasion of Antiviral Innate Immunity by Hepatitis C Virus. J Mol Biol. 2014;426:1198-1209. [PMID: 24184198 DOI: 10.1016/j.jmb.2013.10.032] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
32 Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637-650. [PMID: 21616434 DOI: 10.1016/j.immuni.2011.05.006] [Cited by in Crossref: 2169] [Cited by in F6Publishing: 1964] [Article Influence: 216.9] [Reference Citation Analysis]
33 Tomer S, Chawla YK, Duseja A, Arora SK. Dominating expression of negative regulatory factors downmodulates major histocompatibility complex Class-II expression on dendritic cells in chronic hepatitis C infection. World J Gastroenterol 2016;22:5173-82. [PMID: 27298560 DOI: 10.3748/wjg.v22.i22.5173] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
34 Guan YS, He Q. Role of antiviral therapy in the management of hepatocellular carcinoma. Anticancer Drugs 2013;24:337-43. [PMID: 23388161 DOI: 10.1097/CAD.0b013e32835ec39a] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
35 Stevenson NJ, Bourke NM, Ryan EJ, Binder M, Fanning L, Johnston JA, Hegarty JE, Long A, O'Farrelly C. Hepatitis C virus targets the interferon-α JAK/STAT pathway by promoting proteasomal degradation in immune cells and hepatocytes. FEBS Lett 2013;587:1571-8. [PMID: 23587486 DOI: 10.1016/j.febslet.2013.03.041] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
36 Petrovic D, Stamataki Z, Dempsey E, Golden-Mason L, Freeley M, Doherty D, Prichard D, Keogh C, Conroy J, Mitchell S. Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion. Hepatology. 2011;53:1846-1853. [PMID: 21452285 DOI: 10.1002/hep.24327] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
37 Fletcher NF, Yang JP, Farquhar MJ, Hu K, Davis C, He Q, Dowd K, Ray SC, Krieger SE, Neyts J, Baumert TF, Balfe P, McKeating JA, Wong-Staal F. Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology. 2010;139:1365-1374. [PMID: 20538002 DOI: 10.1053/j.gastro.2010.06.008] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
38 Yi Z, Chen J, Kozlowski M, Yuan Z. Innate detection of hepatitis B and C virus and viral inhibition of the response. Cell Microbiol 2015;17:1295-303. [PMID: 26243406 DOI: 10.1111/cmi.12489] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
39 Pelletier S, Bédard N, Said E, Ancuta P, Bruneau J, Shoukry NH. Sustained hyperresponsiveness of dendritic cells is associated with spontaneous resolution of acute hepatitis C. J Virol 2013;87:6769-81. [PMID: 23576504 DOI: 10.1128/JVI.02445-12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
40 Chinnaswamy S. Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions. J Interferon Cytokine Res 2014;34:479-97. [PMID: 24555572 DOI: 10.1089/jir.2013.0113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
41 Daito T, Watashi K, Sluder A, Ohashi H, Nakajima S, Borroto-Esoda K, Fujita T, Wakita T. Cyclophilin inhibitors reduce phosphorylation of RNA-dependent protein kinase to restore expression of IFN-stimulated genes in HCV-infected cells. Gastroenterology. 2014;147:463-472. [PMID: 24786893 DOI: 10.1053/j.gastro.2014.04.035] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
42 Dustin LB. Innate and Adaptive Immune Responses in Chronic HCV Infection. Curr Drug Targets 2017;18:826-43. [PMID: 26302811 DOI: 10.2174/1389450116666150825110532] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
43 Schmidt J, Thimme R, Neumann-Haefelin C. Host genetics in immune-mediated hepatitis C virus clearance. Biomark Med. 2011;5:155-169. [PMID: 21473719 DOI: 10.2217/bmm.11.19] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
44 Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, Timpe JM, Krieger SE, Baumert TF, Tellinghuisen TL, Wong-Staal F, Balfe P, McKeating JA. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol. 2011;85:596-605. [PMID: 20962076 DOI: 10.1128/jvi.01592-10] [Cited by in Crossref: 178] [Cited by in F6Publishing: 120] [Article Influence: 16.2] [Reference Citation Analysis]
45 Yang DR, Zhu HZ. Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war? World J Gastroenterol. 2015;21:3786-3800. [PMID: 25852264 DOI: 10.3748/wjg.v21.i13.3786] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
46 Rajalakshmy AR, Malathi J, Madhavan HN. HCV core and NS3 proteins mediate toll like receptor induced innate immune response in corneal epithelium. Experimental Eye Research 2014;128:117-28. [DOI: 10.1016/j.exer.2014.09.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
47 Horner SM, Park HS, Gale M. Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0. J Virol. 2012;86:3112-3120. [PMID: 22238314 DOI: 10.1128/jvi.06727-11] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
48 Griesbeck M, Valantin MA, Lacombe K, Samri-Hassimi A, Bottero J, Blanc C, Sbihi Z, Zoorob R, Katlama C, Guiguet M, Altfeld M, Autran B; HepACT-VIH study group. Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals. AIDS 2017;31:1223-34. [PMID: 28492391 DOI: 10.1097/QAD.0000000000001455] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
49 Pujantell M, Franco S, Galván-Femenía I, Badia R, Castellví M, Garcia-Vidal E, Clotet B, de Cid R, Tural C, Martínez MA, Riveira-Muñoz E, Esté JA, Ballana E. ADAR1 affects HCV infection by modulating innate immune response. Antiviral Res 2018;156:116-27. [PMID: 29906476 DOI: 10.1016/j.antiviral.2018.05.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
50 Gauthiez E, Habfast-robertson I, Rüeger S, Kutalik Z, Aubert V, Berg T, Cerny A, Gorgievski M, George J, Heim MH, Malinverni R, Moradpour D, Müllhaupt B, Negro F, Semela D, Semmo N, Villard J, Bibert S, Bochud P; the Swiss Hepatitis C Cohort Study. A systematic review and meta-analysis of HCV clearance. Liver Int 2017;37:1431-45. [DOI: 10.1111/liv.13401] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
51 Coccia EM, Battistini A. Early IFN type I response: Learning from microbial evasion strategies. Semin Immunol 2015;27:85-101. [PMID: 25869307 DOI: 10.1016/j.smim.2015.03.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
52 Pan Q, Metselaar HJ, de Ruiter P, Kwekkeboom J, Tilanus HW, Janssen HL, van der Laan LJ. Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha. Liver Transpl. 2010;16:520-526. [PMID: 20373462 DOI: 10.1002/lt.22032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
53 Hodowanec AC, Brady KE, Gao W, Kincaid SL, Plants J, Bahk M, Landay AL, Huhn GD. Characterization of CD4⁺ T-cell immune activation and interleukin 10 levels among HIV, hepatitis C virus, and HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2013;64:232-40. [PMID: 24131865 DOI: 10.1097/QAI.0b013e31829c6de0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
54 Oshiumi H, Miyashita M, Inoue N, Okabe M, Matsumoto M, Seya T. The ubiquitin ligase Riplet is essential for RIG-I-dependent innate immune responses to RNA virus infection. Cell Host Microbe. 2010;8:496-509. [PMID: 21147464 DOI: 10.1016/j.chom.2010.11.008] [Cited by in Crossref: 168] [Cited by in F6Publishing: 151] [Article Influence: 16.8] [Reference Citation Analysis]
55 Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S, Folgori A, Rehermann B. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 2012;56:2060-70. [PMID: 22706965 DOI: 10.1002/hep.25897] [Cited by in Crossref: 102] [Cited by in F6Publishing: 96] [Article Influence: 11.3] [Reference Citation Analysis]
56 Novembrino C, Aghemo A, Ferraris Fusarini C, Maiavacca R, Matinato C, Lunghi G, Torresani E, Ronchi M, Garlaschi MC, Ramondetta M. Interferon-ribavirin therapy induces serum antibodies determining ‘rods and rings’ pattern in hepatitis C patients. J Viral Hepat. 2014;21:944-949. [PMID: 25040504 DOI: 10.1111/jvh.12281] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
57 Provazzi PJS, Rossi LMG, Carneiro BM, Miura VC, Rosa PCR, de Carvalho LR, de Andrade STQ, Fachini RM, Grotto RMT, Silva GF, Valêncio CR, Neto PS, Cordeiro JA, Nogueira ML, Rahal P. Hierarchical assessment of host factors influencing the spontaneous resolution of hepatitis C infection. Braz J Microbiol 2019;50:147-55. [PMID: 30637644 DOI: 10.1007/s42770-018-0008-3] [Reference Citation Analysis]
58 Neufeldt CJ, Joyce MA, Van Buuren N, Levin A, Kirkegaard K, Gale M Jr, Tyrrell DL, Wozniak RW. The Hepatitis C Virus-Induced Membranous Web and Associated Nuclear Transport Machinery Limit Access of Pattern Recognition Receptors to Viral Replication Sites. PLoS Pathog 2016;12:e1005428. [PMID: 26863439 DOI: 10.1371/journal.ppat.1005428] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 13.6] [Reference Citation Analysis]
59 Firdaus R, Biswas A, Saha K, Mukherjee A, Chaudhuri S, Chandra A, Konar A, Sadhukhan PC. Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients. PLoS One. 2014;9:e99126. [PMID: 24914551 DOI: 10.1371/journal.pone.0099126] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
60 Horner SM, Gale M Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 2013;19:879-88. [PMID: 23836238 DOI: 10.1038/nm.3253] [Cited by in Crossref: 208] [Cited by in F6Publishing: 188] [Article Influence: 26.0] [Reference Citation Analysis]
61 Kang JI, Kwon YC, Ahn BY. Modulation of the type I interferon pathways by culture-adaptive hepatitis C virus core mutants. FEBS Lett. 2012;586:1272-1278. [PMID: 22616990 DOI: 10.1016/j.febslet.2012.03.062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
62 Desai MM, Gong B, Chan T, Davey RA, Soong L, Kolokoltsov AA, Sun J. Differential, type I interferon-mediated autophagic trafficking of hepatitis C virus proteins in mouse liver. Gastroenterology 2011;141:674-85, 685.e1-6. [PMID: 21683701 DOI: 10.1053/j.gastro.2011.04.060] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
63 Gokhale NS, Vazquez C, Horner SM. Hepatitis C Virus. Strategies to Evade Antiviral Responses. Future Virol 2014;9:1061-75. [PMID: 25983854 DOI: 10.2217/fvl.14.89] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
64 Giugliano S, Kriss M, Golden-Mason L, Dobrinskikh E, Stone AE, Soto-Gutierrez A, Mitchell A, Khetani SR, Yamane D, Stoddard M, Li H, Shaw GM, Edwards MG, Lemon SM, Gale M Jr, Shah VH, Rosen HR. Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication. Gastroenterology 2015;148:392-402.e13. [PMID: 25447848 DOI: 10.1053/j.gastro.2014.10.040] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 9.7] [Reference Citation Analysis]
65 Dar HA, Zaheer T, Paracha RZ, Ali A. Structural analysis and insight into Zika virus NS5 mediated interferon inhibition. Infect Genet Evol 2017;51:143-52. [PMID: 28365387 DOI: 10.1016/j.meegid.2017.03.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
66 Dafa-Berger A, Kuzmina A, Fassler M, Yitzhak-Asraf H, Shemer-Avni Y, Taube R. Modulation of hepatitis C virus release by the interferon-induced protein BST-2/tetherin. Virology. 2012;428:98-111. [PMID: 22520941 DOI: 10.1016/j.virol.2012.03.011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
67 Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hu W, Eley T, Mcphee F, Hughes E, Kumada H. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. Journal of Hepatology 2013;58:655-62. [DOI: 10.1016/j.jhep.2012.09.037] [Cited by in Crossref: 183] [Cited by in F6Publishing: 170] [Article Influence: 22.9] [Reference Citation Analysis]
68 Del Campo JA, Romero-Gómez M. Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies. World J Gastroenterol 2015;21:10776-82. [PMID: 26478669 DOI: 10.3748/wjg.v21.i38.10776] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
69 Renner I, Funk N, Geissler R, Friedrich S, Penzel A, Behrens SE. Antiviral interferon-beta signaling induced by designed transcription activator-like effectors (TALE). PLoS One 2014;9:e114288. [PMID: 25470486 DOI: 10.1371/journal.pone.0114288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]